Genzyme's Termeer Sells $10M in Stock Despite Company's Woes
No matter how badly Genzyme (GENZ) performs, CEO Henri Termeer just seems to fall ass-backwards into money. On Nov. 23 he sold $10 million in stock at $50.47 a share after exercising 200,000 options at $26.50 per share.
Termeer’s windfall occurred despite the following:
- Genzyme dropped a kidney drug in November that failed to perform in Phase 3 of development.
- The FDA rejected Genzyme’s Lumizyme drug for Pompe Disease, due to manufacturing “deficiencies” at its Allston Landing, Mass., plant.
- It was the second new drug application from Genzyme that the FDA has rejected. It nixed Clolar for leukemia in September.
- Genzyme’s Allston, Mass., plant has been the subject of a five-week FDA inspection.
- Also in November, garbage — steel, rubber and fiber — was found inside some of the drugs coming out the plant.
- Production at the plant was halted in June due to viral contamination.
- The company was warned in February that it wouldn’t pass an inspection unless it cleaned up its act.
It’s not the first set of options that Termeer has cashed out. In May, he took and sold 22,333 options priced at $0 — that’s zero dollars! — netting $544,875. It comes on top of $50 million he received in total compensation over the last three years.
- Related:
- Genzyme Kidney Drug Failed, Too…What Could Possibly Happen Next?
- Genzyme’s Termeer Got $50M in Compensation Over Last 3 Years; Wife Got Trips to Asia on Corporate Jet
- Bring Me the Head of Genzyme CEO Henri Termeer!
- FDA Delays Genzyme’s Lumizyme, Manufacturing Problems Blamed
- Genzyme’s Triple Screwup: Factory Problem Ends Its Monopoly and Puts NDA on Hold
Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. Follow him on Twitter or send him an email.
BNET User Analysis